News >

CAR T-Cell Therapy KTE-X19 Makes Waves in Relapsed/Refractory MCL

Jessica Hergert
Published: Wednesday, Apr 08, 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center

Michael Wang, MD

The addition of BTK inhibitors to the armamentarium in relapsed/refractory mantle cell lymphoma (MCL) has been revolutionary, said Michael Wang, MD––adding that CAR T-cell therapies, such as KTE-X19, are poised to improve outcomes even further for patients who progress on these agents.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication